Project Grant R43TR000190

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess the practicality of a closed-loop medication management system for opioid pain management targeting ambulatory patients with extremity fractures being discharged from the emergency department. The key objectives are to adapt the Addinex system to seamlessly integrate with hospital...

This $190,662 Project Grant award from the National Institute of Justice (NIJ), under the National Institute of Justice Research, Evaluation, and Development Project Grants program (CFDA 16.560), aims to develop methods for the determination of fentanyl analogs in drug mixtures using portable Raman spectroscopy. The primary activities include: 1) Preparing a library of fentanyl spectra and mixtures using optimized surface-enhanced Raman spectroscopy (SERS) methodology; 2) Determining the...

The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...

The National Science Foundation (NSF) Division of Information and Intelligent Systems awarded a $162,827 Project Grant to the University of Wisconsin - Madison, through the University of Wisconsin System, to develop an "Intelligent Pervasive Augmented Reality Therapy (IPAL)" system for managing opioid use disorder (OUD) and addiction. The 1-year project will integrate complementary psychotherapies like cognitive behavioral therapy and heart rate variability biofeedback with immersive...

The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of ODALERT - an innovative wearable device designed to detect and alert users and first responders of potential opioid overdoses. The $800,000 award to Biosensics LLC, a digital health technology company, will support the completion of ODALERT's sensor development, optimization of battery life, deployment of real-time...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a comprehensive fentanyl testing device by Taesun, LLC. The $305,369 award aims to create an integrated device that simplifies the process of fentanyl detection, making it more accessible and user-friendly for use in high-risk environments. The device will combine multiple testing steps, such as crushing, measuring, and...

The National Institute on Drug Abuse (NIDA) awarded Instanosis Inc., a woman-owned small business in Pennsylvania, a $1,576,513 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a rapid, sensitive, and instrument-free oral fluid fentanyl test. This project aims to create the first FDA-cleared oral fluid fentanyl rapid test that is 10 times more sensitive, has a 5-minute readout time (4 times faster), and requires 100 mL of oral fluid (10 times less volume)...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...

The National Institute of Justice (NIJ) awarded a $2,000,000 Cooperative Agreement under the Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) to The Fredric Rieders Family Renaissance Foundation. The award, effective January 1, 2025 through December 31, 2027, will establish the Novel Psychoactive Substance Discovery, Education, and Reporting Institute (NPS DISCERN). The project aims to rapidly identify emerging drugs and changes in drug markets by characterizing...